Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts. Show more
Location: PO Box 30, Winchester, MA, 01890, United States | Website: https://www.synlogictx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
14.16M
52 Wk Range
$0.90 - $1.88
Previous Close
$1.24
Open
$1.20
Volume
2,054
Day Range
$1.20 - $1.25
Enterprise Value
-2.417M
Cash
17.27M
Avg Qtr Burn
-4.456M
Insider Ownership
11.26%
Institutional Own.
64.74%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SYNB1353 Details Homocystinuria | Phase 2 Initiation | |
SYNB8802 Details Primary hyperoxaluria | Phase 1 Update | |
SYNB1891 Details Solid tumor/s, Cancer | Failed Discontinued | |
Labafenogene marselecobac (previously SYNB1934) Details Phenylketonuria | Failed Discontinued |